October 12, 2026

CDC: Measles cases surpass 4,000 in 2026

CDC data show that 96% of cases are outbreak-associated, with adults accounting for 40% of cases, up from 29% in 2025.

MDSpire News

October 09, 2026

FDA approves atezolizumab for dMMR colon cancer

In the phase 3 ATOMIC trial, adjuvant atezolizumab plus chemotherapy halved the risk of recurrence or death in stage 3 patients.

MDSpire News

October 09, 2026

FDA approves olanzapine injection for schizophrenia

All 3 monthly doses improved schizophrenia symptoms versus placebo in the phase 3 SOLARIS trial.

MDSpire News

October 09, 2026

FDA approves pritelivir for refractory HSV lesions

In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.

MDSpire News

October 09, 2026

CDC flags neuro symptoms after unapproved botulinum toxin

None of the 3 symptomatic patients knew the injected product lacked FDA approval.

MDSpire News

October 08, 2026

FDA flags potential cardiac risk with evenamide

Four deaths among evenamide-treated patients prompted FDA concerns about possible fatal arrhythmias, although a causal link remains unconfirmed.

MDSpire News

October 08, 2026

CDC Ebola update: Outbreak outpaces 2018 surge

More than 120 CDC personnel have been deployed to affected countries as the agency responds to the world's second-largest Ebola outbreak on record.

MDSpire News

October 07, 2026

FDA grants Temab-A dual Breakthrough status

The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.

MDSpire News

October 07, 2026

FDA approves first therapy for symptomatic dermographism

The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.

MDSpire News

October 01, 2026

300K settlement follows unlawful prescribing claims

The federal settlement resolves allegations of unlawful controlled substance prescribing and absent patient records and restricts future DEA registration for certain controlled substances.

MDSpire News